Cyclins and breast cancer

Journal of Mammary Gland Biology and Neoplasia

Volumn 9, Issue 1, 2004, Pages 95-104

  Sutherland, Robert L ^a   Musgrove, Elizabeth A ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Breast cancer; Cell cycle; Cyclin D1; Cyclin E; Steroid hormones

Indexed keywords

CYCLIN D; CYCLIN E; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR; RAS PROTEIN; STEROID;

BREAST CANCER; BREAST DEVELOPMENT; BREAST EPITHELIUM; CANCER RESISTANCE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SPECIFICITY; GENE OVEREXPRESSION; MITOGENESIS; MOUSE; NONHUMAN; PHASE TRANSITION; PROTEIN FUNCTION; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; CYCLIN E; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; ONCOGENE PROTEINS;

EID: 4344560652     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:JOMG.0000023591.45568.77     Document Type: Review

References (83)

1. D. Hanahan and R. A. Weinberg (2000). The hallmarks of cancer. Cell 100:57-70.
2. M. Malumbres and M. Barbacid (2001). To cycle or not to cycle: A critical decision in cancer. Nat. Rev. Cancer 1:222-231.
3. C. J. Ormandy, E. A. Musgrove, R. Hui, R. J. Daly, and R. L. Sutherland (2003). Cyclin D1, EMS1 and 11q13 amplification in human breast cancers. Breast Cancer Res. Treat. 78:323-335.
4. M. F. Buckley, K. J. Sweeney, J. A. Hamilton, R. L. Sini, D. L. Manning, R. I. Nicholson, A. deFazio, C. K. W. Watts, E. A. Musgrove, and R. L. Sutherland (1993). Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2213.
5. K. Keyomarsi and A. B. Pardee (1993). Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 90:1112-1116.
6. C. Gillett, V. Fantl, R. Smith, C. Fisher, J. Bartek, C. Dickson, et al. (1994). Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 54:1812-1817.
7. K. M. Alle, S. M. Henshall, A. S. Field, and R. L. Sutherland (1998). Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin. Cancer Res. 4:847-854.
8. K. Keyomarsi, N. O'Leary, G. Molnar, E. Lees, H. J. Fingert, A. B. Pardee, and E. Cyclin (1994). A potential prognostic marker for breast cancer. Cancer Res. 54:380-385.
9. M. Loden, M. Sighall, N. H. Nielsen, G. Roos, S. O. Emdin, H. Ostlund, et al. (2002). The cyclin D1 high and cyclin E high subgroups of breast cancer: Separate pathways in tumorigenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 21:4680-4690.
10. R. Hui, A. L. Cornish, R. A. McClelland, J. F. Robertson, R. W. Blamey, E. A. Musgrove, et al. (1996). Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin. Cancer Res. 2:923-928.
11. Y. Geng, W. Whoriskey, M. Y. Park, R. T. Bronson, R. H. Medema, T. Li, et al. (1999). Rescue of cyclin D1 deficiency by knockin cyclin E. Cell 97:767-777.
12. D. O. Morgan (1995). Principles of CDK regulation. Nature 374:131-134.
13. 1-phase progression. Genes Dev. 13:1501-1512.
14. N. Dyson (1998). The regulation of E2F by pRB-family proteins. Genes Dev. 12:2245-2262.
15. J. LaBaer, M. D. Garrett, L. F. Stevenson, J. M. Slingerland, C. Sandhu, H. S. Chou, et al. (1997). New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847-862.
16. E. A. Musgrove, J. A. Hamilton, C. S. Lee, K. J. Sweeney, C. K. Watts, and R. L. Sutherland (1993). Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol. 13:3577-3587.
17. J. Lukas, J. Bartkova, M. Welcker, O. W. Petersen, G. Peters, M. Strauss, et al. (1995). Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene 10:2125-2134.
18. R. J. Fiddes, P. W. Janes, S. P. Sivertsen, R. L. Sutherland, E. A. Musgrove, and R. J. Daly (1998). Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells. Oncogene 16:2803-2813.
19. G. A. Colditz (1998). Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl. Cancer Inst. 90:814-823.
20. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E- Cdk2. J. Biol. Chem. 272:10882-10894.
21. J. S. Foster and J. Wimalasena (1996). Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol. Endocrinol. 10:488-498.
22. 1-arrested human breast cancer cells. Oncogene 12:2315-2324.
23. M. D. Planas-Silva and R. A. Weinberg (1997). Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell. Biol. 17:4059-4069.
24. 1 checkpoint. Mol. Cell. Biol. 16:6917-6925.
25. O. W. Prall, E. M. Rogan, E. A. Musgrove, C. K. Watts, and R. L. Sutherland (1998). c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol. Cell. Biol. 18:4499-4508.
26. WAF1/Cip1 is targeted by estrogen to activate cyclin E-Cdk2. J. Biol. Chem. 276:45945-45951.
27. WAF1/CIP1 promoter and interacts with Sp1/Sp3. Proc. Natl. Acad. Sci. U.S.A. 98:4510-4515.
28. E. A. Musgrove, A. Swarbrick, C. S. Lee, A. L. Cornish, and R. L. Sutherland (1998). Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol. Cell. Biol. 18:1812-1825.
29. INK4c in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol. Cell. Biol. 20:2581-2591.
30. R. L. Sutherland, R. E. Hall, and I. W. Taylor (1983). Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau- phase cells. Cancer Res. 43:3998-4006.
31. C. K. Watts, A. Brady, B. Sarcevic, A. deFazio, E. A. Musgrove, and R. L. Sutherland (1995). Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol. 9:1804-1813.
32. J. S. Carroll, O. W. Prall, E. A. Musgrove, and R. L. Sutherland (2000). A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J. Biol. Chem. 275:38221-38229.
33. Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 97:9042-9046.
34. J. S. Carroll, A. Swarbrick, E. A. Musgrove, and R. L. Sutherland (2002). Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: Implications for the antiproliferative effects of antiesgrogens. Cancer Res. 62:3126-3131.
35. Kip1 induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Res. 63:4322-4326.
36. Kip1 deregulation and antiestrogen resistance in human breast cancer cells. J. Biol. Chem. 276:40888-40895.
37. M. Venditti, B. Iwasiow, F. M. Orr, and P. C. Shin (2002). C-myc gene expression alone is sufficent to confer resistance to antiestrogen in human breast cancer cells. Int. J. Cancer 99:35-42.
38. R. Hui, G. Finney, J. S. Carroll, C. S. Lee, E. A. Musgrove, and R. L. Sutherland (2002). Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiesgrogens in T-47D breast cancer cells. Cancer Res. 62:6916-6923.
39. Kip1 association with cyclin E-Cdk2. J. Biol. Chem. 276:47675-47683.
40. T. C. Wang, R. D. Cardiff, L. Zukerberg, E. Lees, A. Arnold, and E. V. Schmidt (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671.
41. W. J. Muller, E. Sinn, P. K. Pattengale, R. Wallace, and P. Leder (1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115.
42. E. Sinn, W. J. Muller, P. K. Pattengale, I. Tepler, R. Wallace, and P. Leder (1987). Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 49:465-475.
43. T. A. Stewart, P. K. Pattengale, and P. Leder (1984). Spontaneous mammary adenocarcinomas in trangenic mice that carry and express MTV/myc fusion genes. Cell 38:627-637.
44. INK4A is critical for growth arrest during mammary involution. Cancer Res. 61:8811-8819.
45. Kip1 in cyclin D2 transgenic mouse mammary gland during development. Oncogene 21:7214-7225.
46. E. Evron, C. B. Umbricht, D. Korz, V. Raman, D. M. Loeb, B. Niranjan, et al. (2001). Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res. 61:2782-2787.
47. M. A. Ciemerych, A. M. Kenney, E. Sicinska, I. Kalaszczynska, R. T. Bronson, and D. H. Rowitch, et al. (2002). Development of mice expressing a single D-type cyclin. Genes Dev. 16:3277-3289.
48. K. J. Sweeney, B. Sarcevic, R. L. Sutherland, and E. A. Musgrove (1997). Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene 14:1329-1340.
49. A. Russell, M. A. Thompson, J. Hendley, L. Trute, J. Armes, and D. Germain (1999). Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene 18:1983-1991.
50. A. Pirkmaier, R. Dow, S. Ganiatsas, P. Waring, K. Warren, A. Thompson, et al. (2003). Alternative mammary oncogenic pathways are induced by D-type cyclins: MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma. Oncogene 22:4425-4443.
51. D. M. Bortner and M. P. Rosenberg (1997). Induction of mammary gland hyperplasia and carcinomas in trangenic mic expressing human cyclin E. Mol. Cell. Biol. 17:453-459.
52. P. Sicinski, J. L. Donaher, S. B. Parker, T. Li, A. Fazeli, H. Gardner, et al. (1995). Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621-630.
53. V. Fantl, G. Stamp, A. Andrews, I. Rosewell, and C. Dickson (1995). Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 9:2364-2372.
54. W. Tong and J. W. Pollard (2001). Genetic evidence for the interactions of cyclin D1 and p27(Kip1). in mice. Mol. Cell. Biol. 21:1319-1328.
55. Y. Geng, Q. Yu, E. Sicinska, M. Das, R. T. Bronson, and P. Sicinski (2001). Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 98:194-199.
56. Q. Yu, Y. Geng, and P. Sicinski (2001). Specific protection against breast cancer by cyclin D1 ablation. Nature 411:1017-1021.
57. P. Jansen-Durr, A. Meichle, P. Steinder, M. Pagano, K. Finke, J. Botz, et al. (1993). Differential modulation of cyclin gene expression by MYC. Proc. Natl. Acad. Sci. U.S.A. 90:3685-3689.
58. K. V. Desai, N. Xiao, W. Want, L. Gangi, J. Greene, J. I. Powell, et al. (2002). Initiating oncogenic event determines gene-expression patterns of human breast cancer models. PNAS 99:6967-6972.
59. D. M. Barnes and C. E. Gillett (1998). Cyclin D1 in breast cancer. Breast Cancer Res. Treat. 52:1-15.
60. D. Weinstat-Saslow, M. J. Merino, R. E. Manrow, J. A. Lawrence, R. F. Bluth, K. D. Wittenbel, et al. (1995). Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat. Med. 1:1257-1260.
61. T. Oyama, K. Kashiwabara, K. Yoshimoto, A. Arnold, and F. Koerner (1998). Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res. 58:2876-2880.
62. C. Gillett, P. Smith, W. Gregory, M. Richards, R. Millis, G. Peters, et al. (1996). Cyclin D1 and prognosis in human breast cancer. Int. J. Cancer 69:92-99.
63. R. Michalides, P. Hageman, H. van Tinteren, L. Houben, E. Wientjens, R. Klompmaker, et al. (1996). A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br. J. Cancer 73:728-734.
64. G. G. McIntosh, J. J. Anderson, I. Milton, M. Steward, A. H. Parr, M. D. Thomas, et al. (1995). Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11:885-891.
65. R. Seshadri, C. S. Lee, R. Hui, K. McCaul, D. J. Horsfall, and R. L. Sutherland (1996). Cyclin D1 application is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin. Cancer Res. 2:1177-1184.
66. E. M. Berns, J. A. Foekens, I. L. van Staveren, W L. van Putten, H. Y. de Koning, H. Portengen, et al. (1995). Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene 159:11-18.
67. I. Bieche, M. Olivi, C. Nogues, M. Vidaud, and R. Lidereau (2002). Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br. J. Cancer 86:580-586.
68. T. S. Hwang, H. S. Han, Y. C. Hong, H. J. Lee, and N. S. Paik (2003). Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathol. Int. 53:74-80.
69. F. S. Kenny, R. Hui, E. A. Musgrove, J. M. Gee, R. W. Blamey, R. I. Nicholson, et al. (1999). Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin. Cancer Res. 5:2069-2076.
70. S. Han, K. Park, B. N. Bae, K. H. Kim, H. J. Kim, Y. D. Kim, et al. (2003). Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer. Oncol. Rep. 10:141-144.
71. K. Keyomarsi, S. L. Tucker, T. A. Buchholz, M. Callister, Y. Ding, G. N. Hortobagyi, et al. (2002). Cyclin E and survival in patients with breast cancer. N. Engl. J. Med. 347:1566-1575.
72. P. N. Span, V. C. Tjan-Heijnen, P. Manders, L. V. Beex, and C. G. Sweep (2003). Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene 22:4898-4904.
73. P. L. Porter, K. E. Malone, P. J. Heagerty, G. M. Alexander, L. A. Gatti, E. J. Firpo, et al. (1997). Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:222-225.
74. E. A. Musgrove, C. S. Lee, M. F. Buckley, and R. L. Sutherland (1994). Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc. Natl. Acad. Sci. U.S.A. 91:8022-8026.
75. 1 cyclin expression in breast cancer cells. Oncogene 16:2865-2878.
76. R. M. Zwijsen, E. Wientjens, R. Klompmaker, J. van der Sman, R. Bernards, and R. J. Michalides (1997). CDK-independent activation of estrogen receptor by cyclin D1. Cell 88:405-415.
77. E. Neuman, M. H. Ladha, N. Lin, T. M. Upton, S. J. Miller, J. DiRenzo, et al. (1997). Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol. Cell. Biol. 17:5338-5347.
78. J. Lamb, S. Ramaswamy, H. L. Ford, B. Contreras, R. V. Martinez, F. S. Kittrell, et al. (2003). A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 114:323-334.
79. O. Coqueret (2002). Linking cyclins to transcriptional control. Gene 299:35-55.
80. J. Lamb, M. H. Ladha, C. McMahon, R. L. Sutherland, and M. E. Ewen (2000). Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol. Cell. Biol. 20:8667-8675.
81. C. A. Zahnow, P. Younes, R. Laucirica, and J. M. Rosen (1997). Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. J. Natl. Cancer Inst. 89:1887-1891.
82. A. Yamamoto, Y. Hashimoto, K. Kohri, E. Ogata, S. Kato, K. Ikeda, et al. (2000). Cyclin E as a coactivator of the androgen receptor. J. Cell Biol. 150:873-880.
83. C. Geisen and T. Moroy (2002). The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein. J. Biol. Chem. 277:39909-39918.